减重手术带来的糖尿病缓解会随着时间推移而减弱（SOS：从 2 年时的 72% 降至 15 年时的 30.4%；Adams：从 75% 降至 51%）。
原始表述
أما هدوء السكري الذي تُرفع رايته، فيتآكل: في SOS انخفض من 72% بعد سنتين إلى 30% فقط بعد 15 سنة، وفي متابعة Adams لـ 12 سنة من 75% إلى 51%.
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
减重手术带来的糖尿病缓解会随着时间推移而减弱（SOS：从 2 年时的 72% 降至 15 年时的 30.4%；Adams：从 75% 降至 51%）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (eltayebat.com); not necessarily Elawady's own words
- 出处
- https://eltayebat.com/rule/bariatric-surgery/
- 归属的不确定性
- Editorial summary/narrative and study selection written by the archive operators; the archive states that the cited research documents harm independently of Dr. Diaa's words.
- 所声称的机制
Not specified.
- 所声称的健康影响
Diabetes relapse.
- 涉及人群
People with type 2 diabetes and obesity
- Elawady 设定的地域限制
not applicable
科学评估
基本正确 – 核心内容正确，但有局限或细微不准确之处。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
That diabetes remission erodes ('relapse within a few years').
2. 哪些内容可证实是正确的？
Correct that remission declines: SOS 72.3% -> 30.4% (A-BAR-23), Adams 75% -> 51% (A-BAR-04), LABS 71% -> 60% at 7 years (A-BAR-06), Mingrone 58.8% of early remitters relapsed (I-BAR-03), ARMMS 18.2% at 7 years and 12.7% at 12 years (I-BAR-02).
3. 哪些内容是错误或夸大的？
'Within a few years' is exaggerated (declines are gradual over 7-15 years). The archive omits that control groups had far lower remission (SOS 6.5%; ARMMS 0%), that microvascular complications were halved (HR 0.44), that diabetes incidence fell by >90% and that 69% of patients in remission at 2 years remained diabetes-free at 12 years, with 12-year remission far higher than in non-operated controls (adjusted OR 8.9 and 14.8) (Adams, A-BAR-04), and that relapsers in Mingrone kept HbA1c around 6.7%. The Arabic SOS headline wrongly says 30.4% of initially remitted patients stayed in remission.
4. 哪些内容仍不明确？
Long-term effect of modern procedures on hard outcomes.
5. 哪些研究支持该说法？
A-BAR-04, A-BAR-06, A-BAR-23, I-BAR-02, I-BAR-03; long-term relapse about 30% after bypass (I-BAR-131); 5-year relapse 33% (bypass) and 42% (sleeve) among remitters (I-BAR-134); Oseberg 5-year remission only 50% (bypass) and 20% (sleeve) (I-BAR-116).
6. 哪些研究与该说法相矛盾？
A-BAR-24, A-BAR-23 (complications), I-BAR-03 (glycaemic control), I-BAR-02; network meta-analysis of 36 RCTs showing more remission and lower HbA1c with surgery than medical therapy (I-BAR-132); fewer microvascular complications (I-BAR-133). The 2026 Cochrane review (I-BAR-143) rates long-term RCT evidence on complete remission as very uncertain.
7. 对德国和欧洲而言情况如何？
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. 关于埃及的已知情况是什么？
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. 合理的实际结论是什么？
对许多人来说，缓解并不是永久的；术后需要继续监测糖尿病。复发并不会抵消比较意义上的益处。
评估详情
- 证据确定性的依据
Consistent across cohorts and RCTs that remission declines; equally consistent that surgery remains superior to medical therapy.
- 来源质量
Numbers correct; framing selective (controls and complication reduction not mentioned); Arabic headline misstates the 30.4% denominator.
- 地区可推广性
European RCT and SOS data.
- 个体例外情况
Relapse more likely with longer diabetes duration and weight regain (general knowledge; not quantified here).
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: In people with type 2 diabetes, does remission after bariatric surgery decline over time, and how does this compare with medical therapy?
研究问题详解 (PICO)
- 人群
- Adults with type 2 diabetes and obesity
- 干预或暴露
- Bariatric surgery
- 对照
- Medical/lifestyle therapy; early vs late follow-up
- 地域范围
- universal biology
- 结局指标
- Diabetes remission
- Relapse
- HbA1c
- Microvascular complications
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
SOS: diabetes after 15 years
SOS: remission fell from 72.3% at 2 years to 30.4% at 15 years.
- 实际结果
- 72.3% -> 30.4% (controls 16.4% -> 6.5%).
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Non-randomised
US study: diabetes 5 years after bypass vs sleeve
PCORnet: among remitters, a third (bypass) to 42% (sleeve) relapsed within 5 years.
- 实际结果
- 5-y relapse 33.1% vs 41.6%.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- EHR definitions
Italian 10-year diabetes surgery trial
Mingrone RCT: 58.8% of 2-year remitters relapsed by 10 years.
- 实际结果
- Relapse 58.8%; relapsers HbA1c ~6.7%.
- 方法学质量
- high (RCT)
- 相关性
- direct
- 局限
- Small
哪些证据不支持该说法？
Network meta-analysis of trials: surgery vs medicines for diabetes
Network meta-analysis of 36 RCTs: surgery yields more remission and lower HbA1c than medical therapy.
- 实际结果
- All procedures except plication increased complete remission vs medical therapy.
- 方法学质量
- high
- 相关性
- direct - contradicts the implied message that surgery fails
- 局限
- Mostly <5 y
SOS: diabetes after 15 years
Same SOS data: microvascular complications halved.
- 实际结果
- HR 0.44.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Non-randomised
Cochrane review: surgery for obesity with type 2 diabetes
Kiesswetter et al.. Cochrane Database Syst Rev 2026 · PMID 42610488 · DOI 10.1002/14651858.CD015622.pub2 Meta分析已核查摘要新增Cochrane NMA: HbA1c and partial remission improve, but long-term complete remission evidence from RCTs is very uncertain.
- 实际结果
- RYGB HbA1c MD -1.44%; SG -1.01%.
- 方法学质量
- high (Cochrane)
- 相关性
- direct; tempers both sides
- 局限
- Few RCT participants
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Remission erodes substantially over years (the archive numbers are correct), but surgery still keeps better glycaemic control and fewer complications than medical therapy on average.
为什么有些研究权重更大
RCTs and SOS long-term data; Cochrane review sets limits on certainty.
因果关系是否已确立？ 是，已确立 Relapse is linked to weight regain and diabetes duration; RCTs confirm surgery superiority short-to-medium term.
仍存在的不确定性
Effect of modern procedures on hard outcomes over decades.
合理的结论
Mostly true as stated; incomplete as an argument against surgery.
为什么研究结果看起来互相矛盾？
No real conflict: erosion of remission over time and superiority over medical therapy are both shown by the same studies.
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Diet after surgery influences relapse.
- 食品原产地
- Not applicable (surgical procedure, not a food).
- 污染物
- Not applicable (surgical procedure, not a food).
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian data found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI symmetry; illustrative share in remission at 5 years – HRs symmetric; illustrative remission at 5 y ~58% (RYGB) and ~49% (SG) after accounting for relapse (ignores timing). 已重新计算
- Reproduce 5-y remission risk differences – RD 29.5% and 33.5% reproduced from counts. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Durability of diabetes remission after surgery
- 起始等级
- 高（随机试验）
- 降级理由
- imprecision (small long-term RCTs)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: Standards of Care in Diabetes-2026, Section 8 (I-DIAB-113) (2026) · 原始文献
Consider metabolic surgery in type 2 diabetes with BMI >=30 (>=27.5 Asian American) (A); long-term medical and behavioural support with routine micronutrient and metabolic monitoring (B); routine psychosocial screening after surgery (C); text cites lower relapse after RYGB than sleeve (5-y relapse 33.1% vs 41.6%).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (TITLE:"diabetes") AND (TITLE:"relapse" OR TITLE:"recurrence" OR TITLE:"long-term remission" OR TITLE:"durability") AND (TITLE:"bariatric" OR TITLE:"metabolic surgery" OR TITLE:"sleeve" OR TITLE:"gastric bypass") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis" OR TITLE:"randomized" OR TITLE:"randomised") | 支持性证据 | 2 | |
| PubMed | 2026年10月26日 | (bariatric surgery[ti] OR gastric bypass[ti] OR sleeve gastrectomy[ti]) AND type 2 diabetes AND (relapse[ti] OR recurrence[ti]) AND 2019:2026[dp] | 支持性证据 | 27 | |
| Europe PMC | 2026年10月26日 | (TITLE:"metabolic surgery" OR TITLE:"bariatric surgery") AND (TITLE:"medical therapy" OR TITLE:"medical treatment") AND TITLE:"type 2 diabetes" AND (TITLE:"long-term" OR TITLE:"10-year" OR TITLE:"12-year" OR TITLE:"meta-analysis") AND PUB_YEAR:[2020 TO 2026] | 反对性证据 | 4 | |
| PubMed | 2026年10月26日 | (metabolic surgery[ti] OR bariatric surgery[ti]) AND (medical therapy[tiab] OR medical treatment[tiab]) AND type 2 diabetes[ti] AND (meta-analysis[pt]) AND randomized AND 2019:2026[dp] | 反对性证据 | 9 | |
| PubMed | 2026年10月26日 | "Obesity and Weight Management for the Prevention and Treatment of Diabetes" AND Standards of Care in Diabetes | 指南 | 80 | |
| Europe PMC | 2026年10月26日 | JOURNAL:"Cochrane Database Syst Rev" AND (TITLE:"surgery for weight loss" OR TITLE:"bariatric" OR TITLE:"obesity surgery" OR TITLE:"surgery for obesity") | 指南 | 13 | |
| PubMed | 2026年10月26日 | McTigue KM[au] AND sleeve gastrectomy AND gastric bypass AND diabetes AND JAMA Surg[ta] | 双向 | 2 |
待解决的问题
Predictors of durable remission; long-term outcomes of sleeve vs bypass in Egyptian patients.
核查深度如何？
13 项相关研究：3 项核查了全文（其中 2 项进行了结构化偏倚风险评估），10 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本正确 (中)
Unchanged (MOSTLY_TRUE, moderate). New meta-analyses confirm relapse rates and surgery superiority; Cochrane review adds that long-term RCT certainty is low. Safety note preserved.
新来源: I-BAR-116 I-BAR-131 I-BAR-134 I-BAR-132 I-BAR-133 I-DIAB-113 I-BAR-143
通俗解释
档案网站称，减重手术对糖尿病的益处会逐渐消退。确实，许多糖尿病得到缓解的人后来会复发：在瑞典，缓解率从两年时的 72% 降至 15 年时的 30%。但没有做手术的人情况要差得多（只有 6.5% 处于缓解状态），而且术后糖尿病并发症大约减少了一半。因此，复发很常见，但与常规治疗相比，手术仍保持着优势。
与该说法相关的研究
支持该说法的研究 (6)
-
12 years after gastric bypass
Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Half of the patients with diabetes were still in remission after 12 years; new diabetes was about 90% less frequent than in non-operated people.
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term outcomes
- 研究是如何开展的？
Prospective controlled cohort
- 研究了多少人、动物或样本？
1156 adults
- 实际发现了什么？
Remission declines but benefit persists
- 观察到的效应有多大？
Remission 51% at 12 y; incident T2D OR 0.08
- 研究结果对日常生活意味着什么？
Relapse happens, but many stay in remission
- 该研究有哪些局限？
Non-randomized; small diabetic subgroup; many controls later had surgery; mostly women in Utah
- 它对 Elawady 的具体说法说明了什么？
Relapse claim true; 'benefit erodes away' overstated
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Exact causal effect; outcomes for sleeve gastrectomy
-
7 years after bypass or band
Courcoulas AP et al.. JAMA Surg 2018 · PMID 29214306 · DOI 10.1001/jamasurg.2017.5025队列研究被 Tayebat 档案网站引用已核查摘要About 60% of bypass patients with diabetes were still in remission at 7 years.
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Durability
- 研究是如何开展的？
Cohort
- 研究了多少人、动物或样本？
2348
- 实际发现了什么？
Remission 71%->60% (RYGB)
- 观察到的效应有多大？
see results
- 研究结果对日常生活意味着什么？
Most keep benefit, some relapse
- 该研究有哪些局限？
No control
- 它对 Elawady 的具体说法说明了什么？
Partly supports erosion claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Comparison with non-surgical care
-
SOS: diabetes after 15 years
Sjöström L et al.. JAMA 2014 · PMID 24915261 · DOI 10.1001/jama.2014.5988队列研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Remission fell from 72% at 2 years to 30% at 15 years after surgery (controls: 16% to 6.5%); diabetes complications were about halved.
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Diabetes long-term
- 研究是如何开展的？
Prospective matched cohort
- 研究了多少人、动物或样本？
603 with T2D
- 实际发现了什么？
Remission declines; complications fewer
- 观察到的效应有多大？
OR 6.3 at 15 y; HR 0.44 microvascular
- 研究结果对日常生活意味着什么？
Relapse is common, but surgery still did better than usual care
- 该研究有哪些局限？
Attrition; non-randomized
- 它对 Elawady 的具体说法说明了什么？
Relapse true; 'collapse' framing incomplete
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Effect of modern procedures
-
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6随机对照试验独立交叉核查已核查摘要★ 关键研究After 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.
Remission at 5 y only 50% (RYGB) and 20% (SG).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare RYGB and SG in T2D
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
109
- 实际发现了什么？
Bypass better for remission and weight; sleeve more acid reflux
- 观察到的效应有多大？
RD 29.5%
- 研究结果对日常生活意味着什么？
Bypass helps diabetes more but is not a cure
- 该研究有哪些局限？
Small, single centre
- 它对 Elawady 的具体说法说明了什么？
Supports bypass preference for diabetes/reflux; contradicts "complete cure"
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Long-term hard outcomes
-
Meta-analysis: diabetes returning after bypass
Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4Meta分析独立交叉核查已核查摘要About 3 in 10 people whose diabetes went into remission after bypass later relapsed; relapse was less common than after sleeve.
Long-term relapse ~30% after RYGB.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Relapse after RYGB
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
17 studies
- 实际发现了什么？
Relapse 30%
- 观察到的效应有多大？
HR 0.73 vs SG
- 研究结果对日常生活意味着什么？
Remission is not always permanent
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports erosion claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Effect on complications
-
US study: diabetes 5 years after bypass vs sleeve
McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087队列研究独立交叉核查已核查摘要★ 关键研究Diabetes remission was slightly more common and relapse less common after bypass; still, about 1 in 3 remitted bypass patients relapsed within 5 years.
5-y relapse 33% (RYGB) and 42% (SG) among remitters.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare T2D outcomes RYGB vs SG
- 研究是如何开展的？
Cohort
- 研究了多少人、动物或样本？
9,710
- 实际发现了什么？
Relapse 33% vs 42%
- 观察到的效应有多大？
Relapse HR 0.75
- 研究结果对日常生活意味着什么？
Bypass a bit better; neither is a guaranteed cure
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports relapse claim; contradicts "complete cure"
- 研究结果是否适用于德国和欧洲？
Plausible
- 从该研究中明确不能得出什么结论？
Hard outcomes
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (3)
-
STAMPEDE: surgery vs medicines for diabetes
Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估After 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Diabetes RCT
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
150
- 实际发现了什么？
Surgery better
- 观察到的效应有多大？
29%/23% vs 5%
- 研究结果对日常生活意味着什么？
Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines
- 该研究有哪些局限？
Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'benefit erodes away'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Hard outcomes
-
Network meta-analysis of trials: surgery vs medicines for diabetes
De Luca et al.. Diabetes Obes Metab 2023 · PMID 37272316 · DOI 10.1111/dom.15117Meta分析独立交叉核查已核查摘要★ 关键研究Across 36 trials, weight-loss operations led to more diabetes remission and lower blood sugar than medical treatment.
RCTs show surgery superior to medical therapy for remission and HbA1c despite later relapse.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Surgery vs medical therapy in T2D
- 研究是如何开展的？
NMA of RCTs
- 研究了多少人、动物或样本？
36 RCTs
- 实际发现了什么？
Surgery better
- 观察到的效应有多大？
not in abstract
- 研究结果对日常生活意味着什么？
Surgery helps diabetes more than medicines alone
- 该研究有哪些局限？
Short follow-up
- 它对 Elawady 的具体说法说明了什么？
Puts relapse in context
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Lifelong effect
-
Meta-analysis: eye and kidney damage in diabetes after surgery
Obeso-Fernández et al.. Surg Obes Relat Dis 2023 · PMID 37169666 · DOI 10.1016/j.soard.2023.02.024Meta分析独立交叉核查已核查摘要People with diabetes who had surgery had fewer eye and kidney complications than those treated with medicines alone.
Lower microvascular complications after surgery.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Microvascular outcomes
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
160,072
- 实际发现了什么？
Less retinopathy, nephropathy, ESRD
- 观察到的效应有多大？
OR 0.29-0.41
- 研究结果对日常生活意味着什么？
Benefit even if diabetes returns
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Context for relapse
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Causation
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (4)
-
Diabetes 12 years after randomized surgery vs medicine
Courcoulas AP et al.. JAMA 2024 · PMID 38411644 · DOI 10.1001/jama.2024.0318随机对照试验独立交叉核查已核查摘要★ 关键研究Blood sugar control stayed better after surgery; full remission was uncommon in both groups but more frequent after surgery (12.7% vs 0%).
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term T2D
- 研究是如何开展的？
Pooled RCT follow-up
- 研究了多少人、动物或样本？
262
- 实际发现了什么？
Surgery better; remission declines
- 观察到的效应有多大？
HbA1c -1.1% at 12 y
- 研究结果对日常生活意味着什么？
Relapse is common, but surgery keeps an advantage
- 该研究有哪些局限？
Crossover, small
- 它对 Elawady 的具体说法说明了什么？
Partly supports erosion; contradicts 'no benefit'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Mortality
-
Italian 10-year diabetes surgery trial
Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0随机对照试验独立交叉核查已核查摘要★ 关键研究More than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.
The diabetes remission achieved by bariatric surgery erodes over time (SOS: 72% at 2 years to 30.4% at 15 years; Adams: 75% to 51%).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Durability
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
60
- 实际发现了什么？
Relapse frequent; control better
- 观察到的效应有多大？
RR complications 0.07
- 研究结果对日常生活意味着什么？
Relapse does not mean the benefit is lost
- 该研究有哪些局限？
Tiny
- 它对 Elawady 的具体说法说明了什么？
Partly supports
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Generalizability
-
US diabetes standards 2026: weight loss and type 2 diabetes
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008指南 / 立场声明独立交叉核查已核查全文★ 关键研究Losing more than 10% of body weight can lead to remission of type 2 diabetes and reduce the need for insulin.
Endorses surgery while acknowledging relapse; requires ongoing monitoring.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide weight management.
- 研究是如何开展的？
Guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Weight loss >10% may induce remission.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Weight loss is a powerful treatment for type 2 diabetes.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Supports the T2D kernel of C-DIAB-03.
- 研究结果是否适用于德国和欧洲？
European guidance agrees.
- 从该研究中明确不能得出什么结论？
Not applicable to T1D.
-
Cochrane review: surgery for obesity with type 2 diabetes
Kiesswetter et al.. Cochrane Database Syst Rev 2026 · PMID 42610488 · DOI 10.1002/14651858.CD015622.pub2Meta分析独立交叉核查已核查摘要★ 关键研究Trials show more weight loss and better blood sugar after surgery, but long-term data on complete diabetes remission, serious harms and deaths are very uncertain.
Long-term complete remission very uncertain in RCTs; HbA1c and partial remission improved.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Benefits/harms of MBS in T2D
- 研究是如何开展的？
Cochrane NMA
- 研究了多少人、动物或样本？
15,282
- 实际发现了什么？
Weight and HbA1c better; remission/mortality very uncertain
- 观察到的效应有多大？
RYGB weight MD -17%
- 研究结果对日常生活意味着什么？
Surgery helps, but long-term certainty is limited
- 该研究有哪些局限？
Few RCT participants
- 它对 Elawady 的具体说法说明了什么？
Partly supports erosion claim; does not show harm
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Precise long-term effects
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
埃及
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
在我的国家适用什么？
一般科学评估
基本正确 缓解常常会减弱，但对糖尿病而言，手术仍优于常规治疗。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Weight and Metabolic Outcomes 12 Years after Gastric Bypass.. Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
- Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study.. Courcoulas AP et al.. JAMA Surg 2018 · PMID 29214306 · DOI 10.1001/jamasurg.2017.5025
- Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.. Sjöström L et al.. JAMA 2014 · PMID 24915261 · DOI 10.1001/jama.2014.5988
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
- Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.. Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4
- Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study.. McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869
- Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta-analysis and network meta-analysis of randomized controlled trials.. De Luca et al.. Diabetes Obes Metab 2023 · PMID 37272316 · DOI 10.1111/dom.15117
- Benefits of bariatric surgery on microvascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis.. Obeso-Fernández et al.. Surg Obes Relat Dis 2023 · PMID 37169666 · DOI 10.1016/j.soard.2023.02.024
- Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes.. Courcoulas AP et al.. JAMA 2024 · PMID 38411644 · DOI 10.1001/jama.2024.0318
- Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.. Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008
- Metabolic and bariatric surgery in adults with obesity and diabetes mellitus: a network meta-analysis.. Kiesswetter et al.. Cochrane Database Syst Rev 2026 · PMID 42610488 · DOI 10.1002/14651858.CD015622.pub2